Irish Startup Snags $120M for Heart Failure Implant
FIRE1 raised $120 million for its Norm system — a heart failure monitor implant that seeks to keep patients out of the hospital.
Amgen to Buy Horizon Therapeutics for $28B, Edging Out Sanofi in Bidding War
Sanofi submitted the first unsolicited offer to acquire Horizon Therapeutics, but Amgen ultimately won what became a competitive bidding process. Amgen says Horizon's drug lineup complements its own portfolio of autoimmune and inflammatory disorder products.
presented by
The 3 Best Options to Buy Telemedicine Carts for Neurology Care
Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors.
Alkermes Weighs Splitting Off Cancer Biz as Separate, Publicly Traded Company
Alkermes says separating cancer from its portfolio and pipeline of neuroscience products could put the company on a path to profitability. Meanwhile, the new cancer company would be an independent and publicly traded entity with a lead immunotherapy in pivotal testing for two types of cancer.
Jazz Pharma joins the bispecific cancer drug chase via Zymeworks licensing deal
Jazz Pharmaceuticals is paying Zymeworks $50 million up front for rights to develop zanidatamab, a bispecific antibody cancer drug currently in two pivotal clinical trials. It’s the second bispecific antibody pact of the week, following Gilead Sciences’ deal to secure an option on a MacroGenics drug in early clinical development.
Novartis pays $100M to get Mallinckrodt’s ticket for a speedier FDA drug review
Novartis is acquiring an FDA priority review voucher from Mallinckrodt Pharmaceuticals. The $100 million price tag is in the neighborhood of the going rate for these vouchers, which grant a company a shorter regulatory review timeline for a drug that addresses a rare or neglected disease.
Werewolf cancer drug strikes right note with Jazz Pharma, sparking licensing deal
Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a drug candidate that expands the company’s scope to immuno-oncology.
The Human Algorithm: What AI Can’t Replace in Pharma Engagement
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
Theravance’s lead drug fails in Phase 3, triggers a restructuring cutting 75% of staff
The clinical trial failure of Theravance Biopharma’s most advanced internal program, a drug for a rare blood pressure disorder, is leading to a companywide restructuring. Going forward, the biotech will focus on developing drugs for respiratory disorders.
Theravance’s Janssen Biotech-partnered ulcerative colitis drug flops in Phase 2
The Theravance Biopharma drug is the lead program in an alliance with Johnson & Johnson subsidiary Janssen Biotech, which paid $100 million up front to develop the JAK inhibitor for intestinal diseases. Following the Phase 2 failure, Theravance said it will minimize spending on that program.
Severe skin burns now have a new FDA-approved regenerative medicine treatment
Mallinckrodt Pharmaceuticals received FDA approval for its engineered skin product, StrataGraft, a treatment for serious thermal burns. The product is the latest to be reviewed under a new designation for regenerative medicines.
Bouncing back from FDA rejection, Alkermes psychiatric drug wins approval
Alkermes antipsychotic drug Lybalvi now has FDA approval. Though the field of neuropsychiatric drugs is crowded with generic medications, Alkermes believes Lybalvi, designed to mitigate the weight gain side effect common with mood disorder drugs, could have an advantage.
presented by
6 Aesthetic Certification Programs That Include Both Theory and Practical Training
Explore top-tier aesthetic certification programs that blend theory with hands-on training — perfect for health care pros ready to elevate their practice
FDA approves Horizon Therapeutics’ drug for thyroid eye disease
The drug, Tepezza, is described as the first-ever drug treatment for thyroid eye disease, a debilitating disease usually treated with surgery.
The one regret of Omar Ishrak, Medtronic’s retiring CEO
Ishrak has led the company for nearly nine years and will retire at the end of the fiscal year in late April turning over the reins to his deputy Geoff Martha who, like Ishrak, came to Medtronic from GE Healthcare.
Allergan recalls Biocell breast implants, warns physicians not to use them
The company initiated the voluntary recall of textured Biocell breast implants and tissue expanders after it received a warning from the FDA that they were linked to some cases of a type of T-cell lymphoma.
Supreme Court rejects Allergan, Saint Regis Mohawk appeal in patent case
The rejection brings to an end an effort by the drugmaker and Native American tribe to invoke sovereign immunity to protect patents covering the dry-eye drug Restasis.
These companies are bringing 3D modeling to the EHR
Through a new partnership, physician practices utilizing DrChrono's mobile EHR solution can directly access 3D4Medical's 3D interactive anatomy models.